AFFIRM: A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy.

Trial Profile

AFFIRM: A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs Enzalutamide (Primary)
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms AFFIRM
  • Sponsors Medivation
  • Most Recent Events

    • 30 Oct 2017 Results of an exploratory analysis assessing the the association between health-related quality of life and clinical outcomes in two phase III trials (AFFIRM and PREVAIL), published in the European Journal of Cancer
    • 10 Jun 2017 Biomarkers information updated
    • 24 May 2017 Results of exploratory analysis assessing benefits of enzalutamide through FACT-P in mCRPC clinical trials (AFFIRM and PREVAIL), presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top